AU2121488A - Lectines fixing beta-d-galactoside - Google Patents

Lectines fixing beta-d-galactoside

Info

Publication number
AU2121488A
AU2121488A AU21214/88A AU2121488A AU2121488A AU 2121488 A AU2121488 A AU 2121488A AU 21214/88 A AU21214/88 A AU 21214/88A AU 2121488 A AU2121488 A AU 2121488A AU 2121488 A AU2121488 A AU 2121488A
Authority
AU
Australia
Prior art keywords
lectines
galactoside
sequence
fixing beta
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU21214/88A
Other versions
AU616195B2 (en
Inventor
Arthur Donny Strosberg
Vivian Teichberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ideon Corp
Original Assignee
Ideon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideon Corp filed Critical Ideon Corp
Publication of AU2121488A publication Critical patent/AU2121488A/en
Application granted granted Critical
Publication of AU616195B2 publication Critical patent/AU616195B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to amino acid sequences reproducing at least in part the sequence of animal and human lectines. The sequence of amino acids comprises a skeleton which is comprised of at least the following amino acids and in the following positions: <IMAGE> . Application particularly to the diagnostic of tumoral affections.
AU21214/88A 1987-07-21 1988-07-18 Lectines fixing beta-d-galactoside Ceased AU616195B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8710288A FR2618439B1 (en) 1987-07-21 1987-07-21 SEQUENCES OF AMINO ACIDS REPRODUCING AT LEAST IN PART THE SEQUENCE OF ANIMAL AND HUMAN LECTINS, THEIR PROCESSES FOR OBTAINING THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
FR8710288 1987-07-21

Publications (2)

Publication Number Publication Date
AU2121488A true AU2121488A (en) 1989-02-13
AU616195B2 AU616195B2 (en) 1991-10-24

Family

ID=9353362

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21214/88A Ceased AU616195B2 (en) 1987-07-21 1988-07-18 Lectines fixing beta-d-galactoside

Country Status (7)

Country Link
EP (1) EP0368920B1 (en)
JP (1) JPH03502446A (en)
AT (1) ATE90363T1 (en)
AU (1) AU616195B2 (en)
DE (1) DE3881698T2 (en)
FR (1) FR2618439B1 (en)
WO (1) WO1989000581A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693760A (en) * 1988-04-14 1997-12-02 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using HL-60 related lectins
FR2651581B1 (en) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique MEANS FOR THE DIAGNOSIS OF DEMYELINIZING NEUROPATHIES, IN PARTICULAR MULTIPLE SCLEROSIS.
FR2741883B1 (en) 1995-12-05 1998-02-20 Ass Pour Le Dev De La Biothera COMPOUNDS WITH LECTIN PROPERTIES, AND BIOLOGICAL APPLICATIONS THEREOF
CA2919473A1 (en) 2013-07-24 2015-01-29 Dana-Farber Cancer Institute, Inc. Anti-galectin-1 monoclonal antibodies and fragments thereof

Also Published As

Publication number Publication date
DE3881698T2 (en) 1993-11-25
FR2618439B1 (en) 1990-05-25
EP0368920A1 (en) 1990-05-23
ATE90363T1 (en) 1993-06-15
DE3881698D1 (en) 1993-07-15
AU616195B2 (en) 1991-10-24
JPH03502446A (en) 1991-06-06
FR2618439A1 (en) 1989-01-27
WO1989000581A1 (en) 1989-01-26
EP0368920B1 (en) 1993-06-09

Similar Documents

Publication Publication Date Title
AU2080988A (en) Esters of 13-trans-retinoic acid
CA2219502A1 (en) Methods and formulations for modulating the human sexual response
AP9700919A0 (en) Modulators of body weight corresponding acids and proteins diagnostic and therapeutic uses thereof
GR3020613T3 (en) Cosmetic and dermatological compositions containing an association of ceramides and linoleic acids, their preparation.
DE60119919D1 (en) FREE AMINOIC COMPOSITION
BR9608067A (en) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
AU7264187A (en) Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems
ATE203907T1 (en) DERMATOLOGICAL PREPARATION FOR THE TREATMENT OF ACTINIC KERATOSIS
DK319484A (en) IMIDAZOL-2-YLTHIOALCANIC ACIDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
AU2121488A (en) Lectines fixing beta-d-galactoside
EP0227619A3 (en) New protein and its use
MX9102086A (en) COMPLEXES CONTAINING S (+) PHENYLALCANIC AND AMINO-SUGAR ACIDS
DE68919468D1 (en) Preparation and isolation of a mineral acid salt of an amino acid methyl ester.
AU4803890A (en) Use of basic amino acids to solubilize immunoglobulins
ATE353019T1 (en) STEREOISOMERS OF FATTY ACID ANALOGUES FOR DIAGNOSTIC IMAGING
NO873626D0 (en) PROCEDURE FOR PREPARING PHARMACEUTICAL PHARMACEUTICAL PREPARATIONS OF PHENYLKINOLINE CARBOXYL ACIDS.
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci
NO170930C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 4-OXO-3-QUINOLINE CARBOXYL ACIDS
AU1614795A (en) Use of an enzyme for assisting an animal to digest protein
ES2074264T3 (en) HYDROQUINONE AMINO ACID ESTERS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING THEM.
CA2271735A1 (en) Magnetic resonance blood pool agents
FI945353A0 (en) Enzymatic process for the preparation of (S) -6-methoxyl-alpha-methyl-2-naphthaleneacetic acid
ATE37873T1 (en) PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 1,4DIHYDROPYRIDINE.
EP0257418A3 (en) Oxirane-pseudo-oligosaccharides, process for their synthesis, their use and pharmaceutical preparations
CS8703287A1 (en) Method of 2-benzothiazolsulphenic acid&#39;s sulphenamides preparation